Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REP-001
- Development stage
- Unknown
- Lead developer
- Repurpose.AI
- Modality
- Small Molecules
01
Overview
**REP-001** is a reported small-molecule drug candidate attributed to Repurpose.AI and described in secondary sources as being intended for **gastric disorders**. Publicly accessible information is extremely limited: the specific active ingredient, molecular target, mechanism of action, formulation, route of administration, and exact development program have not been clearly disclosed in reliable primary sources reviewed. Available company-profile and press-release references suggest it was one of several internally identified repurposing assets and was characterized as a Phase II/III-ready asset in older secondary descriptions, but the precise indication and current status remain insufficiently verified.
Beyond the preview
Go deeper on REP-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REP-001.